BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 35467476)

  • 1. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M; Cremers JF; Krallmann C; Kliesch S
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
    Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
    J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase.
    Tishova Y; Kalinchenko S; Mskhalaya G; Hackett G; Livingston M; König C; Strange R; Zitzmann M; Mann A; Maarouf A; Ramachandran S
    Diabetes Obes Metab; 2024 Jun; 26(6):2147-2157. PubMed ID: 38433502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency.
    Haider KS; Zitzmann M; Ramachandran P; König CS; Hackett G; Haider A; Saad F; Desnerck P; Strange R; Mann A; Ramachandran S
    Aging Male; 2024 Dec; 27(1):2357548. PubMed ID: 38812251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study.
    Handelsman DJ; Grossmann M; Yeap BB; Stuckey BGA; Shankara-Narayana N; Conway AJ; Inder WJ; McLachlan RI; Allan C; Jenkins AJ; Jesudason D; Bracken K; Wittert GA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e25-e31. PubMed ID: 37623257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRACK_9: Testosterone replacement assessment: Classical vs. functional hypogonadism‐knowledge from a 9‐year study.
    Zitzmann M; Cremers JF; Krallmann C; Soave A; Kliesch S
    Andrology; 2024 Mar; ():. PubMed ID: 38488343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men.
    Hackett G; Mann A; Haider A; Haider KS; Desnerck P; König CS; Strange RC; Ramachandran S
    World J Mens Health; 2024 Feb; ():. PubMed ID: 38449452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 12 Months' Treatment with Testosterone Undecanoate on Markers for Erythropoietic Activity and Safety Aspects in Transgender and Cisgender Hypogonadal Men.
    Lethin K; Aardal E; Lood Y; Ekman B; Wahlberg J
    J Appl Lab Med; 2024 Mar; 9(2):223-236. PubMed ID: 38085088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial.
    Pencina KM; Travison TG; Artz AS; Lincoff AM; Nissen SE; Flevaris P; Chan A; Li X; Diegel SA; Wannemuehler K; Bhasin S
    JAMA Netw Open; 2023 Oct; 6(10):e2340030. PubMed ID: 37889486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, Single-Center Clinical Trial.
    Rivero MJ; Reddy R; Muthigi A; Reddy R; Han S; Reis IM; Patel M; Ramasamy R
    World J Mens Health; 2024 Jan; ():. PubMed ID: 38164037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications.
    Swerdloff RS; Pak Y; Wang C; Liu PY; Bhasin S; Gill TM; Matsumoto AM; Pahor M; Surampudi P; Snyder PJ
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3280-7. PubMed ID: 26120790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product.
    Bernstein JS; Dhingra OP
    Ther Adv Urol; 2024; 16():17562872241241864. PubMed ID: 38606384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments and challenges for new and emergent preparations for male hypogonadism treatment.
    Corona G; Sparano C; Rastrelli G; Vignozzi L; Maggi M
    Expert Opin Investig Drugs; 2023; 32(11):1071-1084. PubMed ID: 37943011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study.
    Alwani M; Al-Zoubi RM; Al-Qudimat A; Yassin A; Aboumarzouk O; Al-Rumaihi K; Talib R; Al-Ansari A
    Ann Med Surg (Lond); 2021 Sep; 69():102748. PubMed ID: 34471531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Testosterone--a "fountain of youth" for ageing men? Brief assessment of the efficacy and safety of androgen substitution in healthy men].
    Perleth M
    Z Arztl Fortbild Qualitatssich; 2007; 101(7):487-97. PubMed ID: 18183870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose ingestion does not lower testosterone concentrations in men on testosterone therapy.
    Dhindsa S; Ghanim H; McPhaul MJ; Ghoshal AK; Dandona P
    J Investig Med; 2024 Jun; 72(5):487-491. PubMed ID: 38644376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of testosterone, the androgen receptor, and hypothalamic-pituitary-gonadal axis in depression in ageing Men.
    Hauger RL; Saelzler UG; Pagadala MS; Panizzon MS
    Rev Endocr Metab Disord; 2022 Dec; 23(6):1259-1273. PubMed ID: 36418656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone replacement therapy: association with mortality in high-risk patient subgroups.
    Mann A; Strange RC; König CS; Hackett G; Haider A; Haider KS; Desnerck P; Ramachandran S
    Andrology; 2023 Dec; ():. PubMed ID: 38148671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Analysis between Hypogonadal Symptoms and Changes in Body Composition and Physical Fitness after Testosterone Treatment in Men with Testosterone Deficiency.
    Park TY; Choi MY; Kim DS; Yeo JK; Rajasekaran M; Park MG
    World J Mens Health; 2024 Jan; 42(1):178-187. PubMed ID: 37118963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bulbocavernosus muscle area as a novel marker for hypogonadism.
    Gupta N; Carvajal M; Jurewicz M; Gilbert BR
    Asian J Urol; 2017 Jan; 4(1):3-9. PubMed ID: 29264199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.